Compare +50 FDA Predicate Strategy Providers

If your team is preparing a 510(k), predicate strategy quality often determines whether your review moves cleanly or stalls in Additional Information cycles. This directory gives you a practical framework to compare +50 provider options, align scope to device risk, and avoid overpaying for generic deliverables.

How to Use This Directory

This page is intentionally procurement-focused: the goal is not to rank firms by marketing visibility, but to help you identify which operating model matches your device class, evidence maturity, and internal bandwidth. In our experience, teams get better outcomes when they evaluate providers against objective dimensions: predicate screening depth, measurable gap logic, writing quality for SE rationale, and turn-time reliability under document churn.

For practical comparison, segment providers into three buckets. First are boutique regulatory specialists with senior reviewer-caliber strategy but limited throughput; these are strong for borderline classification and novel technology deltas. Second are mid-size lifecycle firms that combine predicate work with testing program orchestration; these are useful when your team needs one accountable coordinator. Third are documentation-heavy outsourcing groups that can generate volume quickly; these can work if your strategy is stable, but they usually require strong in-house QA to avoid generic narrative language.

Provider Evaluation Scorecard

Commercial Models You Should Expect

Most predicate strategy engagements follow one of four pricing structures: fixed-scope memo packages, phase-based retainers, hourly advisory, or hybrid fixed-plus-revision bands. Fixed scope is easiest to buy but risky if your classification path changes. Pure hourly gives flexibility but can drift without explicit decision gates. For most 510(k) teams, phase-based structures with clear outputs per phase tend to create the best accountability.

When negotiating, define outputs at artifact level. Examples: “top 8 candidate predicates with exclusion rationale,” “SE difference matrix with evidence references,” and “final narrative package aligned to device description and labeling.” The more precise your artifact list, the less likely you are to pay for iterative rework that should have been included.

When to Keep Work In-House vs Outsource

Keep predicate work in-house when your team already has strong domain context, stable device definition, and access to prior submission intelligence. Outsource when your intended use or technological delta is likely to trigger challenging reviewer questions, or when your internal regulatory writer cannot absorb the drafting window. Hybrid models usually perform best: internal team owns decision rights, provider accelerates deep analysis and structured writing.

Minimum Deliverables Checklist Before You Sign

• Predicate candidate longlist and shortlist with explicit exclusion logic.
• Difference matrix with impact tags: low, moderate, high SE risk.
• Evidence gap table with required test or justification artifacts.
• Draft SE narrative with tracked assumptions and unresolved items.
• Revision policy defining included rounds and turnaround time.

Related 510(k) Resources

Connect this provider decision to your broader submission plan:

• Predicate Device Analysis Guide
• Substantial Equivalence Narrative Guide
• 510(k) Submission Checklist
• 510(k) Fees and Timeline

Citations

[1] FDA, Premarket Notification 510(k): fda.gov/medical-devices/.../premarket-notification-510k

[2] 21 CFR Part 807 Subpart E (Premarket Notification): ecfr.gov/.../part-807/subpart-E

[3] FDA CDRH Learn: 510(k) Basics and Resources: fda.gov/.../cdrh-learn

[4] FDA eSTAR Program: fda.gov/.../estar-program